490 related articles for article (PubMed ID: 30021550)
1. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
[TBL] [Abstract][Full Text] [Related]
2. Apoptin enhances the oncolytic properties of Newcastle disease virus.
Wu Y; Zhang X; Wang X; Wang L; Hu S; Liu X; Meng S
Intervirology; 2012; 55(4):276-86. PubMed ID: 21865658
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells.
Jiang K; Li Y; Zhu Q; Xu J; Wang Y; Deng W; Liu Q; Zhang G; Meng S
BMC Cancer; 2014 Jul; 14():551. PubMed ID: 25078870
[TBL] [Abstract][Full Text] [Related]
4. The control of anaplastic thyroid carcinoma cell lines by oncolytic poxviruses.
Mundi N; Um S; Yoo J; Rizzo G; Black M; Pinto N; Palma DA; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Virus Res; 2014 Sep; 190():53-9. PubMed ID: 25038405
[TBL] [Abstract][Full Text] [Related]
5. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy.
Hu L; Sun S; Wang T; Li Y; Jiang K; Lin G; Ma Y; Barr MP; Song F; Zhang G; Meng S
Am J Cancer Res; 2015; 5(12):3612-23. PubMed ID: 26885450
[TBL] [Abstract][Full Text] [Related]
7. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
[TBL] [Abstract][Full Text] [Related]
8. [Mechanisms of in vitro anti-tumor effects of a Newcastle disease virus].
Meng S; Bai H; Hu M; Liu W; Wang L; Wu Y; Jiao X; Fan J
Wei Sheng Wu Xue Bao; 2009 Apr; 49(4):512-7. PubMed ID: 19621640
[TBL] [Abstract][Full Text] [Related]
9. Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells.
Wang X; Shao X; Gu L; Jiang K; Wang S; Chen J; Fang J; Guo X; Yuan M; Shi J; Ding C; Meng S; Xu Q
J Cell Mol Med; 2020 Apr; 24(7):4286-4297. PubMed ID: 32100392
[TBL] [Abstract][Full Text] [Related]
10. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death.
Elankumaran S; Rockemann D; Samal SK
J Virol; 2006 Aug; 80(15):7522-34. PubMed ID: 16840332
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.
Kazimirsky G; Jiang W; Slavin S; Ziv-Av A; Brodie C
Stem Cell Res Ther; 2016 Oct; 7(1):149. PubMed ID: 27724977
[TBL] [Abstract][Full Text] [Related]
12. STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells.
Shao X; Wang X; Guo X; Jiang K; Ye T; Chen J; Fang J; Gu L; Wang S; Zhang G; Meng S; Xu Q
Front Oncol; 2019; 9():436. PubMed ID: 31192135
[No Abstract] [Full Text] [Related]
13. Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK/NF-κB/IκBα pathway.
Ch'ng WC; Abd-Aziz N; Ong MH; Stanbridge EJ; Shafee N
Cell Oncol (Dordr); 2015 Aug; 38(4):279-88. PubMed ID: 25930675
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral Virotherapy with Wild-Type Newcastle Disease Virus in Carcinoma Krebs-2 Cancer Model.
Yurchenko KS; Glushchenko AV; Gulyaeva MA; Bi Y; Chen J; Shi W; Adamenko LS; Shestopalov AM
Viruses; 2021 Mar; 13(4):. PubMed ID: 33806229
[TBL] [Abstract][Full Text] [Related]
15. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.
Koks CA; Garg AD; Ehrhardt M; Riva M; Vandenberk L; Boon L; De Vleeschouwer S; Agostinis P; Graf N; Van Gool SW
Int J Cancer; 2015 Mar; 136(5):E313-25. PubMed ID: 25208916
[TBL] [Abstract][Full Text] [Related]
16. Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus.
Bian J; Wang K; Kong X; Liu H; Chen F; Hu M; Zhang X; Jiao X; Ge B; Wu Y; Meng S
Arch Virol; 2011 Aug; 156(8):1335-44. PubMed ID: 21625975
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer.
Chai Z; Zhang P; Fu F; Zhang X; Liu Y; Hu L; Li X
Virol J; 2014 May; 11():84. PubMed ID: 24885546
[TBL] [Abstract][Full Text] [Related]
18. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
19. Newcastle disease virus strain AF2240 as an oncolytic virus: A review.
Kalyanasundram J; Hamid A; Yusoff K; Chia SL
Acta Trop; 2018 Jul; 183():126-133. PubMed ID: 29626432
[TBL] [Abstract][Full Text] [Related]
20. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
